| abstract |
The preparation and use of 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open ring 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6’’-acetate and Ethyl 17-L-[(2’-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6’,6’’-diacetate sophorolipids are antibacterial, antiviral and/or anti-spermidical agents. |